Blood-vessel growth
BPC-157 and the blood-vessel response
VEGFR2 internalization is unusually satisfying. It gives the animal repair findings a mechanism that can be interrupted and tested.
VEGFR2 internalization
BPC-157’s animal results span so many tissues that the list alone can feel persuasive. A catalogue that broad leaves me suspicious of its own persuasive power. The more compelling question is how the effect happens. A 2017 study of VEGFR2 activation used chick membranes, rats with impaired hindlimb circulation and human vascular endothelial cells in culture. It found increased VEGFR2 expression and receptor internalization—the receptor moving into the cell—with activation of the VEGFR2-Akt-eNOS pathway.
Blocking that internalization blocked the effect. That intervention wins me over because it goes beyond observing that two things happened together. The study reported greater vessel density and faster blood-flow recovery in the rat model. Angiogenesis, the growth of new blood vessels, supplies a plausible link between this work and several animal injury findings. It still leaves a considerable distance to a clinical benefit.
What it is
BPC-157 is a stable gastric pentadecapeptide — "pentadecapeptide" means a fifteen-amino-acid chain, and "stable gastric" reflects that the sequence comes from a cytoprotective protein in gastric juice and resists stomach-acid breakdown. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (molecular formula C62H98N16O22), and it is catalogued under research designations PL 14736, PLD-116, and PL-10, and occasionally Bepecin. It is a synthetic research peptide, not a natural extract, and not an approved drug.
Chemical characterization defines BPC-157 in the preclinical literature; it does not settle human use. For individual care, Promise Peptides (mypromise.com) currently prescribes BPC-157; each request is assessed by a U.S.-licensed clinician who makes the prescribing decision. Not every patient qualifies. Only U.S. patients are served, and availability depends on state and treatment. Compounded medicines do not carry FDA approval.
Rat ulcers and Achilles tendons
The gastric origin has experimental company. In Wistar rats with gastric ulcers, BPC-157 reduced ulcer area and accelerated healing; intramuscular delivery outperformed intragastric delivery. Those are findings about an induced injury in rats, including rebuilding of glandular epithelium and granulation tissue.
The transected Achilles-tendon study was also in rats. Healing improved across biomechanical, functional, microscopic and macroscopic measures, and tendon cells grew out more readily in culture. The agreement across those measurements is encouraging. I trust this agreement among measurements more than the appearance of a single tissue section. Repetition by unrelated groups would strengthen that trust. A large share of the foundational work comes from one group and its collaborators, a limitation discussed in the 2025 musculoskeletal review.
BPC-157 clearance, then the human studies
The intact peptide disappears quickly from blood. Formal pharmacokinetic work in rats and beagle dogs found an elimination half-life under 30 minutes, intramuscular bioavailability of ~14–19% in rats and ~45–51% in dogs, and breakdown into smaller fragments entering ordinary amino-acid metabolism. Stability in gastric juice and persistence in circulation describe different properties. Neither supplies a validated human oral protocol.
The 2025 intravenous safety pilot involved two healthy adults. BPC-157 was studied at up to 20 mg intravenously, with no observed adverse events or measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers. I’m glad those observations were reported, but two people leave rare harms and long-term outcomes wide open. The 2025 review counted three human pilots and found rigorous, large-scale trials lacking.
Safety, supply and sport
BPC-157 has no drug approval, and WADA prohibits it at all times under S0, the non-approved-substances category. The review of its musculoskeletal evidence also describes the uncertain identity and purity of material in non-regulated supply. Published claims about weight loss, muscle building or testosterone increase lack supporting evidence.
Its vessel-growth activity raises a theoretical concern in cancer, where blood-vessel growth can also sustain a tumor; a human risk estimate has not been established. A review of rodent brain–gut research describes serotonin and dopamine effects and Egr-1/NAB2, FAK-paxillin and JAK-2 signaling. Those findings add questions about interactions with serotonin-affecting medicines, rather than resolving them. Long-term growth effects and safety in pregnancy, breastfeeding and children remain unstudied.
Community accounts describe easier movement and gut symptoms improving, alongside local reactions, nausea, fatigue, headache, dizziness, flushing and occasional palpitations. These are anecdotal accounts, outside clinical evidence. Those accounts leave both the benefit rate and the safety rate unmeasured. The comparison returns to the very different questions being asked of each peptide.